Whitefort Capital Management LP Has $17.02 Million Stake in Liquidia Co. (NASDAQ:LQDA)

Whitefort Capital Management LP increased its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 119.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,702,025 shares of the company's stock after purchasing an additional 927,546 shares during the period. Liquidia accounts for 7.8% of Whitefort Capital Management LP's portfolio, making the stock its 6th largest holding. Whitefort Capital Management LP owned 2.22% of Liquidia worth $17,020,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company's stock valued at $42,587,000 after purchasing an additional 43,352 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after buying an additional 230,820 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company's stock worth $2,496,000 after buying an additional 32,076 shares in the last quarter. HighVista Strategies LLC grew its stake in shares of Liquidia by 48.6% in the 3rd quarter. HighVista Strategies LLC now owns 180,947 shares of the company's stock worth $1,809,000 after buying an additional 59,193 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Liquidia by 735.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock worth $1,402,000 after buying an additional 123,402 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Lifesci Capital assumed coverage on shares of Liquidia in a research note on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Bank of America reduced their price target on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating for the company in a report on Tuesday, August 20th. Finally, Scotiabank started coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and an average target price of $24.00.

Liquidia Price Performance

Shares of NASDAQ LQDA traded down $0.46 during midday trading on Friday, hitting $11.02. 737,165 shares of the company's stock were exchanged, compared to its average volume of 974,535. The company has a market cap of $932.73 million, a PE ratio of -7.04 and a beta of 0.22. Liquidia Co. has a twelve month low of $6.86 and a twelve month high of $16.99. The firm's fifty day simple moving average is $10.82 and its 200-day simple moving average is $11.33.

Insider Transactions at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now owns 812,193 shares of the company's stock, valued at $9,023,464.23. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction on Friday, October 18th. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the transaction, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. This trade represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,007 shares of company stock valued at $245,780 over the last three months. 30.10% of the stock is currently owned by insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).